Australia markets closed

Landos Biopharma, Inc. (LABP)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
22.47+0.12 (+0.54%)
At close: 04:00PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 69.71M
Enterprise value 40.70M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)3.01
Enterprise value/revenue N/A
Enterprise value/EBITDA 1.09

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3648.32%
S&P500 52-week change 326.36%
52-week high 322.84
52-week low 32.50
50-day moving average 318.27
200-day moving average 37.79

Share statistics

Avg vol (3-month) 325.26k
Avg vol (10-day) 36.34k
Shares outstanding 53.13M
Implied shares outstanding 63.12M
Float 81.33M
% held by insiders 19.89%
% held by institutions 151.58%
Shares short (30 Apr 2024) 41.43k
Short ratio (30 Apr 2024) 40.08
Short % of float (30 Apr 2024) 40.09%
Short % of shares outstanding (30 Apr 2024) 40.05%
Shares short (prior month 28 Mar 2024) 44.9k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:10
Last split date 326 May 2023

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-39.38%
Return on equity (ttm)-70.67%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA N/A
Net income avi to common (ttm)-24.8M
Diluted EPS (ttm)-4.00
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)29M
Total cash per share (mrq)9.28
Total debt (mrq)N/A
Total debt/equity (mrq)N/A
Current ratio (mrq)4.43
Book value per share (mrq)7.43

Cash flow statement

Operating cash flow (ttm)-20.8M
Levered free cash flow (ttm)-12.13M